Literature DB >> 17310422

Nonmydriatic teleretinal imaging improves adherence to annual eye examinations in patients with diabetes.

Paul R Conlin1, Barry M Fisch, Anthony A Cavallerano, Jerry D Cavallerano, Sven-Erik Bursell, Lloyd M Aiello.   

Abstract

We studied whether nonmydriatic digital retinal imaging with remote interpretation (teleretinal imaging) in the ambulatory care setting affected adherence to annual dilated eye examinations among patients with diabetes. We randomly assigned 448 patients to a teleretinal imaging group or a control group. We measured the number of patients who had dilated eye examinations within 12 months of group assignment and the agreement for level of diabetic retinopathy between teleretinal imaging and the eye examinations. The teleretinal imaging group (n = 223) had significantly more dilated eye examinations than the control group (n = 225). Teleretinal imaging and eye examination results showed significant correlation and moderate agreement. Cataract and smaller pupil size were significantly associated with ungradable retinal images. Two-thirds of patients with ungradable images had other ocular findings. Patients reported high satisfaction with nonmydriatic teleretinal imaging. Nonmydriatic teleretinal imaging improves diabetic retinopathy assessment rates.

Entities:  

Mesh:

Year:  2006        PMID: 17310422     DOI: 10.1682/jrrd.2005.07.0117

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  32 in total

1.  Detection of anaemia from retinal fundus images via deep learning.

Authors:  Yun Liu; Avinash V Varadarajan; Akinori Mitani; Abigail Huang; Subhashini Venugopalan; Greg S Corrado; Lily Peng; Dale R Webster; Naama Hammel
Journal:  Nat Biomed Eng       Date:  2019-12-23       Impact factor: 25.671

2.  Telemedicine and Diabetic Retinopathy: Review of Published Screening Programs.

Authors:  Kevin Tozer; Maria A Woodward; Paula A Newman-Casey
Journal:  J Endocrinol Diabetes       Date:  2015-11-11

3.  [Diabetic retinopathy: comparison of the diagnostic features of ultra-widefield scanning laser ophthalmoscopy Optomap with ETDRS 7-field fundus photography].

Authors:  M Kernt; F Pinter; I Hadi; C Hirneiss; C Haritoglou; A Kampik; M W Ulbig; A S Neubauer
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

4.  Cost-effectiveness of Autonomous Point-of-Care Diabetic Retinopathy Screening for Pediatric Patients With Diabetes.

Authors:  Risa M Wolf; Roomasa Channa; Michael D Abramoff; Harold P Lehmann
Journal:  JAMA Ophthalmol       Date:  2020-10-01       Impact factor: 7.389

5.  Long-term Comparative Effectiveness of Telemedicine in Providing Diabetic Retinopathy Screening Examinations: A Randomized Clinical Trial.

Authors:  Steven L Mansberger; Christina Sheppler; Gordon Barker; Stuart K Gardiner; Shaban Demirel; Kathleen Wooten; Thomas M Becker
Journal:  JAMA Ophthalmol       Date:  2015-05       Impact factor: 7.389

Review 6.  Clinical Components of Telemedicine Programs for Diabetic Retinopathy.

Authors:  Mark B Horton; Paolo S Silva; Jerry D Cavallerano; Lloyd Paul Aiello
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

7.  Teleretinal screening for diabetic retinopathy in six Los Angeles urban safety-net clinics: final study results.

Authors:  Omolola Ogunyemi; Sheba George; Lauren Patty; Senait Teklehaimanot; Richard Baker
Journal:  AMIA Annu Symp Proc       Date:  2013-11-16

8.  Automated detection of proliferative retinopathy in clinical practice.

Authors:  Audrey Karperien; Herbert F Jelinek; Jorge J G Leandro; João V B Soares; Roberto M Cesar; Alan Luckie
Journal:  Clin Ophthalmol       Date:  2008-03

9.  Teleretinal imaging to screen for diabetic retinopathy in the Veterans Health Administration.

Authors:  Anthony A Cavallerano; Paul R Conlin
Journal:  J Diabetes Sci Technol       Date:  2008-01

Review 10.  Diabetic Eye Screening: Knowledge and Perspectives from Providers and Patients.

Authors:  Yao Liu; Rebecca Swearingen
Journal:  Curr Diab Rep       Date:  2017-08-31       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.